Short answer
Allogene Therapeutics, Inc. (ALLO) filed an 8-K current report with the SEC on May 13, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition). Termination ends Overland’s exclusive rights to develop, manufacture, and commercialize four CAR T targets across Greater China and other Asian markets.
Allogene Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Termination ends Overland’s exclusive rights to develop, manufacture, and commercialize four CAR T targets across Greater China and other Asian markets
- Allogene relinquished future milestone payments up to $40.0 million and mid-single-digit royalties on regional net sales
- Prior economics included $40.0 million cash upfront and $79.0 million in Overland preferred-stock consideration
- No termination payment; mutual release eliminates claims through the agreement date
- Allogene’s Overland ownership reduced to approximately 3%, with revised governance rights under the amended shareholders’ agreement
Item 2.02 · Results of Operations and Financial Condition
- Corporate update and Q1 2026 financial results announced for quarter ended March 31, 2026
- Press release dated May 13, 2026 contains the substantive operating and financial details
- Investor focus: pipeline progress, cash runway, and quarterly expense trends in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Allogene Therapeutics, Inc. 8-K filings
Get the next ALLO 8-K as it lands
Follow ALLO for push alerts, or ask the research agent what this filing means.